Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial.
Loebel A, et al.
Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
Loebel A, et al.
Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
Loebel A, et al.
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Meltzer HY, et al.
Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M, et al.
Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study.
Nasrallah HA, et al.
Lurasidone in the treatment of schizophrenia: a 6 week, placebo-controlled study.
Ogasa M, et al.
back
are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.
